ZA200303013B - Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders. - Google Patents
Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders. Download PDFInfo
- Publication number
- ZA200303013B ZA200303013B ZA200303013A ZA200303013A ZA200303013B ZA 200303013 B ZA200303013 B ZA 200303013B ZA 200303013 A ZA200303013 A ZA 200303013A ZA 200303013 A ZA200303013 A ZA 200303013A ZA 200303013 B ZA200303013 B ZA 200303013B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- melagatran
- substance
- composition
- pharmaceutically
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 49
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title claims description 44
- 229960002137 melagatran Drugs 0.000 title claims description 43
- 230000000302 ischemic effect Effects 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 11
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 description 21
- 229960005080 warfarin Drugs 0.000 description 19
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 18
- 208000032843 Hemorrhage Diseases 0.000 description 17
- 208000005189 Embolism Diseases 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- 208000034158 bleeding Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 7
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000005665 thrombophilia Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000013194 cardioversion Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 208000018578 heart valve disease Diseases 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 208000006887 mitral valve stenosis Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229940019333 vitamin k antagonists Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010058016 Infective thrombosis Diseases 0.000 description 1
- 206010048620 Intracardiac thrombus Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010043626 Thrombosis mesenteric vessel Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/705,912 US6462021B1 (en) | 2000-11-06 | 2000-11-06 | Use of low molecular weight thrombin inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200303013B true ZA200303013B (en) | 2004-07-16 |
Family
ID=24835453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200303013A ZA200303013B (en) | 2000-11-06 | 2003-04-16 | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6462021B1 (ja) |
| EP (1) | EP1333855A1 (ja) |
| JP (2) | JP2004512376A (ja) |
| KR (1) | KR20040004431A (ja) |
| CN (1) | CN1455679A (ja) |
| AU (2) | AU2001225625B2 (ja) |
| BR (1) | BR0017367A (ja) |
| CA (1) | CA2428012A1 (ja) |
| IL (1) | IL155431A0 (ja) |
| MX (1) | MXPA03003980A (ja) |
| NO (1) | NO20032006L (ja) |
| NZ (1) | NZ525487A (ja) |
| WO (1) | WO2002036157A1 (ja) |
| ZA (1) | ZA200303013B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| SE0201373D0 (sv) * | 2002-05-06 | 2002-05-06 | Astrazeneca Ab | Combination therapy |
| SE0201374D0 (sv) * | 2002-05-06 | 2002-05-06 | Astrazeneca Ab | Pharmaceutical combination |
| MXPA05002662A (es) | 2002-09-09 | 2005-09-20 | Trigen Ltd | Sales de metal multivalente de acidos boronicos para el tratamiento de trombosis. |
| US7371729B2 (en) | 2002-09-09 | 2008-05-13 | Trigen Limited | Boronic acid salts useful in parenteral formulations |
| GB0306615D0 (en) * | 2003-03-22 | 2003-04-30 | Astrazeneca Ab | New use |
| WO2008009638A2 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| SE504185C2 (sv) | 1994-11-08 | 1996-12-02 | Astra Ab | Lagringsstabil vattenlösning för infusion av trombininhibitorer |
| SE9404196D0 (sv) | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
| DE69625230T2 (de) | 1995-10-24 | 2003-09-04 | Merck & Co., Inc. | Thrombininhibitoren |
| TW541316B (en) * | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
| SE9602145D0 (sv) | 1996-05-31 | 1996-05-31 | Astra Ab | New improved formulation for treatment of thromboembolism |
| SE9603724D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
| SE9704401D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | Matrix pellets for greasy, oily or sticky drug substances |
| SE9704400D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | Porous inorganic particles as carriers for drug substances |
| SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
-
2000
- 2000-11-06 US US09/705,912 patent/US6462021B1/en not_active Expired - Fee Related
- 2000-11-09 KR KR10-2003-7006172A patent/KR20040004431A/ko not_active Application Discontinuation
- 2000-11-09 CN CN00819999A patent/CN1455679A/zh active Pending
- 2000-11-09 EP EP00989076A patent/EP1333855A1/en not_active Withdrawn
- 2000-11-09 IL IL15543100A patent/IL155431A0/xx unknown
- 2000-11-09 AU AU2001225625A patent/AU2001225625B2/en not_active Ceased
- 2000-11-09 AU AU2562501A patent/AU2562501A/xx active Pending
- 2000-11-09 MX MXPA03003980A patent/MXPA03003980A/es active IP Right Grant
- 2000-11-09 WO PCT/SE2000/002204 patent/WO2002036157A1/en active IP Right Grant
- 2000-11-09 NZ NZ525487A patent/NZ525487A/en unknown
- 2000-11-09 CA CA002428012A patent/CA2428012A1/en not_active Abandoned
- 2000-11-09 JP JP2002538966A patent/JP2004512376A/ja active Pending
- 2000-11-09 BR BR0017367-3A patent/BR0017367A/pt not_active IP Right Cessation
-
2003
- 2003-04-16 ZA ZA200303013A patent/ZA200303013B/en unknown
- 2003-05-05 NO NO20032006A patent/NO20032006L/no not_active Application Discontinuation
-
2004
- 2004-10-26 JP JP2004310299A patent/JP2005120098A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002036157A1 (en) | 2002-05-10 |
| JP2004512376A (ja) | 2004-04-22 |
| AU2562501A (en) | 2002-05-15 |
| JP2005120098A (ja) | 2005-05-12 |
| US6462021B1 (en) | 2002-10-08 |
| CN1455679A (zh) | 2003-11-12 |
| EP1333855A1 (en) | 2003-08-13 |
| MXPA03003980A (es) | 2003-08-19 |
| AU2001225625B2 (en) | 2006-06-15 |
| BR0017367A (pt) | 2003-10-07 |
| CA2428012A1 (en) | 2002-05-10 |
| KR20040004431A (ko) | 2004-01-13 |
| NZ525487A (en) | 2004-11-26 |
| IL155431A0 (en) | 2003-11-23 |
| NO20032006D0 (no) | 2003-05-05 |
| NO20032006L (no) | 2003-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080113960A1 (en) | Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor | |
| JP2008505126A (ja) | 血小板凝集薬を用いる併用療法 | |
| ZA200304878B (en) | Medicinal compositions containing aspirin. | |
| US20110230552A1 (en) | Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack | |
| US20060160793A1 (en) | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions | |
| AU2001225625B2 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
| AU2001225625A1 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
| TW201500042A (zh) | 與血液透析有關的低血壓的治療 | |
| JP2023551503A (ja) | 抗血栓剤としてのシクロスポリン類似体の使用 | |
| CA2335280C (en) | Method of treating pulmonary hypertension | |
| US9597322B2 (en) | Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting | |
| KR101162385B1 (ko) | 아테롬성 동맥 경화증을 치료하기 위한 서-방출형 경구몰시도민 조성물 | |
| KR20100137448A (ko) | 혈관성 질병의 예방제 및/또는 치료제 | |
| JP2006506405A (ja) | 透析患者における心血管イベントを減らすためのフォシノプリルの使用 | |
| KR20050018330A (ko) | 혈관장애의 치료 및 예방을 위한 디피리다몰,아세틸살리실산 및 안지오텐신 ⅱ 길항제의 용도 | |
| US20120277264A1 (en) | Antithrombotic agent | |
| JP2005060359A (ja) | 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用 | |
| MXPA03007462A (es) | Uso de dipiridamol, acido acetilsalicilico y un antagonista de la angiotensina ii para el tratamiento y la prevencion de eventos vasculares. | |
| ZA200108544B (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. |